Nov 04, 2020 / 09:30PM GMT
Operator
Good afternoon, and welcome, ladies and gentlemen, to Cytokinetics' Third Quarter 2020 Conference Call. At this time, I would like to inform you that this call is being recorded (Operator Instructions)
I will now turn the call over to Diane Weiser, Cytokinetics Senior Vice President of Corporate Communications and Investor Relations. Please go ahead.
Diane Weiser - Cytokinetics, Incorporated - SVP of Corporate Communications & IR
Good afternoon, and thanks for joining us on the call today. Robert Blum, our President and Chief Executive Officer, will kick off the call with a recap of our top line results from GALACTIC-HF and an overview of our progress during the quarter. Then Fady Malik, our EVP of Research and Development, will provide perspective on the top line results, what we can expect from presentations at AHA and an update on METEORIC-HF, the second Phase III clinical trial of omecamtiv mecarbil. Next, Stuart Kupfer, our SVP and Chief Medical Officer, will update on recent progress with CK-274, our cardiac myosin inhibitor, which is a
Q3 2020 Cytokinetics Inc Earnings Call Transcript
Nov 05, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers